ArticleJB & JS open access
Will the Knee Outlive the Patient? Kaplan-Meier Systematically Overstates the Lifetime Risk of Revision After Total Knee Arthroplasty.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lifetime revision risk after total knee arthroplasty (TKA) is usually estimated from Kaplan-Meier survivorship, which treats death as noninformative censoring and overstates revision incidence when competing mortality is substantial. The bias increases with age. We quantified the discrepancy between Kaplan-Meier and competing-risk estimates and derived the age- and sex-specific probability of dying with the original TKA. Methods: We analyzed 2,920 primary TKAs from a 15-year multisurgeon single-institution database linked to the New Zealand Joint Registry. Revision and death were modelled as competing events using Aalen-Johansen cumulative incidence functions and Fine-Gray subdistribution hazards, with patient-level clustering for bilateral cases. Kaplan-Meier estimates censoring death served as the benchmark. Cohort mortality was compared with the New Zealand population using standardized mortality ratios (SMRs) from 2017 to 2019 life tables. Results: There were 155 revisions and 525 deaths (median follow-up 7.4 years). The 15-year revision estimate was 8.3% by Kaplan-Meier versus 7.4% by competing-risk estimation overall, and 5.6% versus 3.0% in patients aged 85 years or older (relative overestimation >80%). At 10 years, cumulative incidence of revision was 5.7% (95% CI 4.8-6.7) versus 19.9% (18.2-21.8) for death, diverging with age (85 years or older: 3.0% versus 67.6%). 97% of patients aged 75 years or older died with the original TKA. Each 10-year age increment lowered the revision hazard (sHR 0.76, 0.61-0.94) and raised mortality (HR 2.33, 2.02-2.68). Cohort mortality was lower than the general population (SMR 0.73, 0.66-0.79). Among Māori, this relative advantage (SMR 0.66) was absent against the total population (SMR 1.11). Conclusions: Kaplan-Meier systematically overstates absolute lifetime revision incidence after TKA, most in older patients for whom competing mortality dominates. Age- and sex-specific competing-risk estimates provide more accurate preoperative figures and should be reported alongside Kaplan-Meier when presenting long-term revision risk. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.